bepafant has been researched along with Pulmonary Hypertension in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ashino, Y; Fujimura, S; Hoshikawa, Y; Nishimura, T; Noda, M; Ono, S; Tabata, S; Tanita, T; Ueda, S | 1 |
Ono, S; Voelkel, NF | 2 |
Ono, S; Voelkel, NF; Westcott, JY | 1 |
4 other study(ies) available for bepafant and Pulmonary Hypertension
Article | Year |
---|---|
[Lung 3H-thymidine incorporation in monocrotaline (MCT)-treated rats--role of platelet-activating factor (PAF)].
Topics: Animals; Azepines; DNA; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Thymidine; Triazoles | 1994 |
PAF receptor blockade inhibits lung vascular changes in the rat monocrotaline model.
Topics: Animals; Azepines; Blood Pressure; Hydroxyproline; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pulmonary Artery; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Thymidine; Triazoles | 1992 |
PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats.
Topics: Animals; Azepines; Endothelins; Hypertension, Pulmonary; Hypoxia; In Vitro Techniques; Lung; Male; N-Formylmethionine Leucyl-Phenylalanine; Platelet Activating Factor; Pulmonary Circulation; Rats; Triazoles; Vasoconstriction | 1992 |
PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension.
Topics: Animals; Azepines; Cardiomegaly; Hypertension, Pulmonary; Lung; Lung Injury; Male; Monocrotaline; Platelet Activating Factor; Rats; Rats, Inbred Strains; Triazoles | 1991 |